EW

SEC source: 0001225208-25-009066 · doc4.xml · nonDerivative · entry 2

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,001.9103

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $82.27 to $82.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-009066 · doc4.xml · nonDerivative · entry 1

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,021.9103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.

SEC source: 0001225208-25-007990 · doc4.xml · nonDerivative · entry 2

Markowitz Wayne · CIK 0001991414 · CVP, JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,145.8708

SEC source: 0001225208-25-007992 · doc4.xml · nonDerivative · entry 1

Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,926.9331

SEC source: 0001225208-25-007991 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,201

F1 · shares: These restricted stock units were granted on September 11, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-25-007990 · doc4.xml · nonDerivative · entry 1

Markowitz Wayne · CIK 0001991414 · CVP, JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,795.8708

F1 · shares: These restricted stock units were granted on September 11, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-25-007460 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, TMTT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,996

F1 · price: This transaction was executed in multiple trades at prices ranging from $81.9401 to $81.9500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-007321 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,800

Underlying: Common Stock · 8,950 shares

Expires 2026-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-007321 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,900.3913

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-007321 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 215,850.3913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

SEC source: 0001225208-25-006815 · doc4.xml · nonDerivative · entry 1

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,001.9103

F1 · price: This transaction was executed in multiple trades at prices ranging from $79.4500 to $79.4701. The price reported above reflects the weighted average sale price. The reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-006643 · doc4.xml · nonDerivative · entry 1

Bruls Annette · CIK 0002032351 · CVP, EMEACLA

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,171

SEC source: 0001225208-25-006588 · doc4.xml · nonDerivative · entry 1

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,115.9103

SEC source: 0001225208-25-005981 · doc4.xml · derivative · entry 4

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,750

Underlying: Common Stock · 8,950 shares

Expires 2026-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-005981 · doc4.xml · nonDerivative · entry 2

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,900.3913

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $74.8901 to $75.4400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-005981 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 215,850.3913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

SEC source: 0001225208-25-005684 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By Trust

Disclosed balance after: 8,596.5511

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.

F3 · price: This transaction was executed in multiple trades at prices ranging from $77.140 to $77.540 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-005628 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,356.3707

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $77.36 to $77.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-005684 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By Trust

Disclosed balance after: 9,563.5511

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $76.930 to $77.585 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-005388 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, TMTT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,496

SEC source: 0001225208-25-005233 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 25,662.5511

F1 · kind: This transaction involved the reporting person's transfer of 5,815.5511 shares of EW common stock directly held to the reporting person's Family Trust for no consideration.

SEC source: 0001225208-25-005233 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,976

F1 · kind: This transaction involved the reporting person's transfer of 5,815.5511 shares of EW common stock directly held to the reporting person's Family Trust for no consideration.

SEC source: 0001225208-25-005052 · doc4.xml · nonDerivative · entry 3

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 19,847

SEC source: 0001225208-25-005052 · doc4.xml · nonDerivative · entry 2

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,791.5511

SEC source: 0001225208-25-004999 · doc4.xml · nonDerivative · entry 1

BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,926.3707

SEC source: 0001225208-25-004998 · doc4.xml · nonDerivative · entry 1

Chopra Daveen · CIK 0001740963 · CVP, TMTT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,996

SEC source: 0001225208-25-004997 · doc4.xml · nonDerivative · entry 1

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,345.1066

SEC source: 0001225208-25-004995 · doc4.xml · nonDerivative · entry 1

Wood Larry L · CIK 0001440660 · Global President TAVR & Surg

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,900.3913

SEC source: 0001225208-25-004996 · doc4.xml · nonDerivative · entry 1

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,898

SEC source: 0001225208-25-005052 · doc4.xml · nonDerivative · entry 1

Zovighian Bernard J · CIK 0001665141 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,562.5511

SEC source: 0001225208-25-004954 · doc4.xml · nonDerivative · entry 2

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,054

F2 · shares: This restricted stock award was granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004954 · doc4.xml · nonDerivative · entry 1

LORANGER STEVEN R · CIK 0001226924 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,900

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004953 · doc4.xml · nonDerivative · entry 1

LAVIOLETTE PAUL A · CIK 0001191249 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,301

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004955 · doc4.xml · nonDerivative · entry 1

Sequeira Ramona · CIK 0001811081 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,686

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004956 · doc4.xml · nonDerivative · entry 1

VALERIANI NICHOLAS J · CIK 0001263149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,296

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004952 · doc4.xml · nonDerivative · entry 1

STONE HEISZ LESLIE · CIK 0001235408 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,563

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004951 · doc4.xml · nonDerivative · entry 2

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,682

F2 · shares: This restricted stock award was granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004951 · doc4.xml · nonDerivative · entry 1

GALLAHUE KIERAN · CIK 0001308428 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,528

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004950 · doc4.xml · nonDerivative · entry 1

Feinberg David T · CIK 0001486426 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,836

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004949 · doc4.xml · nonDerivative · entry 1

Davis Leslie C. · CIK 0002021765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,583

F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.

SEC source: 0001225208-25-004947 · doc4.xml · derivative · entry 6

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 330 shares

Expires 2025-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-004947 · doc4.xml · nonDerivative · entry 3

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,616.1066

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $74.135 to $74.735. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-004947 · doc4.xml · nonDerivative · entry 2

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,946.1066

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.

SEC source: 0001225208-25-004942 · doc4.xml · derivative · entry 8

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires 2025-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-004942 · doc4.xml · nonDerivative · entry 4

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,098

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024.

F3 · price: This transaction was executed in multiple trades at prices ranging from $74.12 to $74.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-25-004942 · doc4.xml · nonDerivative · entry 3

Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024.

SEC source: 0001225208-25-004947 · doc4.xml · derivative · entry 5

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,225

Underlying: Common Stock · 4,225 shares

Expires not disclosed

F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-25-004947 · doc4.xml · derivative · entry 4

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Common Stock · 21,500 shares

Expires 2032-05-07

F4 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-25-004947 · doc4.xml · nonDerivative · entry 1

Lippis Daniel J. · CIK 0002004380 · CVP, JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,616.1066

F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-25-004948 · doc4.xml · derivative · entry 3

Bruls Annette · CIK 0002032351 · CVP, EMEACLA

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,200

Underlying: Common Stock · 6,200 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.